HIF in Gastric Cancer: Regulation and Therapeutic Target
- PMID: 35956843
- PMCID: PMC9370240
- DOI: 10.3390/molecules27154893
HIF in Gastric Cancer: Regulation and Therapeutic Target
Abstract
HIF means hypoxia-inducible factor gene family, and it could regulate various biological processes, including tumor development. In 2021, the FDA approved the new drug Welireg for targeting HIF-2a, and it is mainly used to treat von Hippel-Lindau syndrome, which demonstrated its good prospects in tumor therapy. As the fourth deadliest cancer worldwide, gastric cancer endangers the health of people all across the world. Currently, there are various treatment methods for patients with gastric cancer, but the five-year survival rate of patients with advanced gastric cancer is still not high. Therefore, here we reviewed the regulatory role and target role of HIF in gastric cancer, and provided some references for the treatment of gastric cancer.
Keywords: HIF; gastric cancer.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Xue X., Kang J.B., Yang X., Li N., Chang L., Ji J., Meng X.K., Zhang H.Q., Zhong Y., Yu S.P., et al. An efficient strategy for digging protein-protein interactions for rational drug design—A case study with HIF-1α/VHL. Eur. J. Med. Chem. 2022;227:113871. doi: 10.1016/j.ejmech.2021.113871. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
